Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 67

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 67
---
 the operating results of the Company's segment for the three and nine months ended September 30, 2025, and 2024:Three months ended September 30,Nine months ended September 30,2025202420252024Total revenues$26,063 $3,695 $72,345 $11,569 Less significant segment expenses:Research and development directly identified to programs1,780 4,916 6,480 18,369 Research and development not directly identified to programs1,652 6,029 3,643 15,374 Selling, general and administrative directly identified to programs5,144 4,864 19,144 12,560 Selling, general and administrative not directly identified to programs11,791 11,344 38,118 26,183 Other segment items:Impairment of intangible assets— — 58,710 — Income tax (benefit) expense(433)— 2,948 — Interest income(2,333)(899)(5,308)(2,366)Depreciation and amortization expense392 1,617 3,692 4,741 Interest expense2,051 2,312 6,029 5,157 Other expense (income), net (a)6,563 6,737 (132,175)1,323 Segment net (loss) income$(544)$(33,225)$71,064 $(69,772)(a) Other expense, net, included in segment net (loss) income includes the gain on the sale of the PRV, foreign currency exchange gains and losses, cost of product revenue (excluding intangible asset amortization), fair value adjustment related to warrant and contingent value right (“CVR”) liabilities, fair value adjustment related to investments, and other overhead expenses.

16

The Company holds long-lived assets in the United States of $2.2 million and $13.4 million as of September 30, 2025, and December 31, 2024, respectively. The Company holds long-lived assets in Europe of $0.4 million and $0.5 million as of September 30, 2025, and December 31, 2024, respectively.

D.    Inventories

The components of inventory are summarized as follows (in thousands):September 30,2025December 31,2024Raw materials$